In Q3'26, GEN's total operating expenses reached $473M USD, comprising $96M in R&D expenses and $377M in SG&A expenses, reflecting a moderate increase from the prior quarter driven primarily by elevated SG&A costs. Over the period from Q4'23 to Q3'26, total operating expenses exhibited volatility with an overall upward trend, rising from $325M to $473M USD, fueled by significant spikes in SG&A expenses—such as a jump to $580M in Q2'24 and sustained growth to $377M in Q3'26—while R&D expenses fluctuated between $77M and $109M, peaking in Q1'26 before a slight decline. This pattern suggests expanding administrative and sales efforts amid relatively stable research investments, warranting monitoring for cost efficiency in future quarters.